Tag Archives: IRDye700

Photoimmuno-antimicrobial therapy for Staphylococcus aureus implant infection

March 8, 2024 by Modulight Content
No comments
Published in: PLoS One Authors: Bruce van Dijk, Sabrina Oliveira, J. Fred F. Hooning van Duyvenbode, F. Ruben H. A. Nurmohamed, Vida Mashayekhi, Irati Beltrán Hernández, Jos van Strijp, Lisanne de Vor, Piet C. Aerts, H. Charles Vogely, Harrie Weinans, Bart C. H. van der Wal  Published in: PLoS One Authors: Bruce van Dijk, Sabrina Oliveira, J. Fred F. Hooning van Duyvenbode, F. Ruben H. A. Nurmohamed, Vida Mashayekhi, Irati Beltrán Hernández, Jos van Strijp, Lisanne de Vor, Piet C. Aerts, H. Charles Vogely, Harrie Weinans, Bart C. H. van der Wal Photoimmuno-antimicrobial therapy (PIAT) was develop to treat implant infections that cause high morbidity and mortality worldwide. Antibody targeting Wall Teichoic Acid surface components of both S. aureus and its biofilm was conjugated to a photosensitizer IRDye700DX and used as Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – December 2022

December 28, 2022 by Modulight Content
No comments
   Modulight Spotlights: LASER-SHARP RESEARCH – December 2022 This month’s research spotlight goes to H. Wakiyama, H. Kobayashi, et al. at National Cancer Institute, USA. Their study, published in Cancer Immunology Research journal, looked into immunological mechanisms behind hyperprogressive disease. Immune checkpoint inhibitors, despite being a major success story in the field of cancer therapy, unfortunately lead to this rapid progression of cancer in some patients, for yet poorly understood reasons. To study this, the research team partially depleted cytotoxic T cells by photoimmunotherapy, using CD8-targeted Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – November 2022

November 16, 2022 by Modulight Content
No comments
   Modulight Spotlights: LASER-SHARP RESEARCH – November 2022 This month’s Spotlight goes to Susumu Yamashita et al. for promising findings on novel light-based therapy for breast cancer treatment, published in a journal Cancer Medicine. Their teams at Olympus and Tokyo University of Agriculture and Technology developed trastuzumab-conjugated photo-absorber (Tra-IR700) which targets HER2-positive breast cancer cells. This treatment strategy is particularly relevant, since HER2 biomarker is associated with poor survival of breast cancer patients and often has intrinsic or acquired resistance to standard trastuzumab therapy. Especially for these patients, Tra-IR700 activated with Continue reading →

Combining photoimmunotherapy with immune checkpoint inhibition

July 14, 2021 by Modulight Content
No comments
Motivation for the study The motivation was to study if photoimmunotherapy could enhance anti-tumor immunity when combined with immune checkpoint inhibition. CD44-targeted photoimmunotherapy was applied against poorly immunogenic, “cold” tumor and antitumor effect was studied alone and in combination with anti-PD-1 immune checkpoint inhibition. Sensitization of this “cold” tumor to immune checkpoint inhibition after photoimmunotherapy would mean that the tumor has been converted into highly immunogenic, “hot” tumor infiltrated with killer T cells mainly responsible for eradicating the tumor. The formation of immunological antitumor memory Continue reading →Customer case The Laboratory of Molecular Theranostics at National Cancer Institute (NCI) is a major research section of the Molecular Imaging Program at National Cancer Institute (NCI) and is led by Dr. Hisataka Kobayashi who is the father of photoimmunotherapy. The ground-breaking research includes the development of imaging and theranostic probes with a particular emphasis on optical probes, which can aid in cancer detection during cancer resection or endoscopy. Dr. Hisataka Kobayashi M.D., PhD Dr. Peter L. Choyke M.D., PhD   Modulight products: ML7710 (multiple channels Continue reading →

Acute cellular and vascular responses to photodynamic therapy using EGFR-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging

January 20, 2020 by Modulight Content
No comments
Published in: Theranostics Authors: Henriette S. de Bruijn, Vida Mashayekhi, Tom J.L. Schreurs, Pieter B.A.A. van Driel, Gustav J. Strijkers, Paul J. van Diest, Clemens W.G.M. Lowik, Ann L.B. Seynhaeve, Timo L.M. ten Hagen, Jeanine J. Prompers, Paul M.P. van Bergen en Henegouwen, Dominic J. Robinson, Sabrina Oliveira    Published in: Theranostics Authors: Henriette S. de Bruijn, Vida Mashayekhi, Tom J.L. Schreurs, Pieter B.A.A. van Driel, Gustav J. Strijkers, Paul J. van Diest, Clemens W.G.M. Lowik, Ann L.B. Seynhaeve, Timo L.M. ten Hagen, Jeanine J. Prompers, Paul M.P. van Bergen en Henegouwen, Dominic J. Robinson, Sabrina Oliveira   Laser was used to study the effectiveness of two EGFR-targeted nanobody-photosensitizer (IRDye700DX) conjugates for PDT both in vivo and in vitro. The biodistribution (by fluorescence imaging), cellular responses and vascular effects of the two prepared conjugates Continue reading →

An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma

February 1, 2018 by Modulight Content
No comments
Published in: Molecular Cancer Therapeutics Authors: Rhonda C. Kines, Isabella Varsavsky, Sanghamitra Choudhary, Debaditya Bhattacharya, Sean Spring, Roger McLaughlin, Shin J. Kang, Hans E. Grossniklaus, Demetrios Vavvas, Stephen Monks, John R. MacDougall, Elisabet de los Pinos, and John T. Schiller    Published in: Molecular Cancer Therapeutics Authors: Rhonda C. Kines, Isabella Varsavsky, Sanghamitra Choudhary, Debaditya Bhattacharya, Sean Spring, Roger McLaughlin, Shin J. Kang, Hans E. Grossniklaus, Demetrios Vavvas, Stephen Monks, John R. MacDougall, Elisabet de los Pinos, and John T. Schiller   The research group studied a novel recombinant papillomavirus-like particle (VLP) drug conjugate and its initial evaluation as a potential treatment for primary uveal melanoma. Laser was used for evaluating tumor-specific targeting and cellular toxicity of their novel IRDye 700DX-conjugated papillomavirus-like particle (AU-011) in vitro Continue reading →

EGFR targeted nanobody–photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer

May 10, 2016 by Modulight
No comments
Published in: Journal of Controlled Release Authors: Pieter B.A.A. van Driel, Martin C. Boonstra, Maxime D. Slooter, Raimond Heukers, Marieke A. Stammes, Thomas J.A. Snoeks, Henriette S. de Bruijn, Paul J. van Diest, Alexander L. Vahrmeijer, Paul M.P. van Bergen en Henegouwen, Cornelis J.H. van de Velde, Clemens W.G.M. Löwik, Dominic J. Robinson, Sabrina Oliveira    Published in: Journal of Controlled Release Authors: Pieter B.A.A. van Driel, Martin C. Boonstra, Maxime D. Slooter, Raimond Heukers, Marieke A. Stammes, Thomas J.A. Snoeks, Henriette S. de Bruijn, Paul J. van Diest, Alexander L. Vahrmeijer, Paul M.P. van Bergen en Henegouwen, Cornelis J.H. van de Velde, Clemens W.G.M. Löwik, Dominic J. Robinson, Sabrina Oliveira   Photodynamic therapy (PDT) induces cell death through local light activation of a photosensitizer (PS) and has been used to treat head and neck cancers. Yet, common PS lack tumor Continue reading →